Global Tumour Vaccine Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Tumour Vaccine market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Tumour Vaccine industry chain, the market status of Lung Cancer (Personalized Vaccine, Off-the shelf Vaccine), Melanoma Cancer (Personalized Vaccine, Off-the shelf Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Tumour Vaccine.

Regionally, the report analyzes the Tumour Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Tumour Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Tumour Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Tumour Vaccine industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Personalized Vaccine, Off-the shelf Vaccine).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Tumour Vaccine market.

Regional Analysis: The report involves examining the Tumour Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Tumour Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Tumour Vaccine:
Company Analysis: Report covers individual Tumour Vaccine players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Tumour Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer, Melanoma Cancer).

Technology Analysis: Report covers specific technologies relevant to Tumour Vaccine. It assesses the current state, advancements, and potential future developments in Tumour Vaccine areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Tumour Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Tumour Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
    Personalized Vaccine
    Off-the shelf Vaccine

Market segment by Application
    Lung Cancer
    Melanoma Cancer
    Gastrointestinal Cancer
    Brain Cancer
    Others

Market segment by players, this report covers
    Pfizer
    Merck & Co Inc
    Eli Lilly and Company
    BioNTech
    Roche Holding AG
    OSE Immunotherapeutics
    Gritstone Bio
    Moderna
    Avidea Technologies
    Vaccibody AS
    Agenus Inc
    Novogene
    ZIOPHARM Oncology
    ISA Pharmaceuticals
    BrightPath Biotherapeutics
    Vaximm AG
    Medigene AG
    Genocea Biosciences Inc
    Advaxis
    Nouscom

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Tumour Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Tumour Vaccine, with revenue, gross margin and global market share of Tumour Vaccine from 2019 to 2024.
Chapter 3, the Tumour Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Tumour Vaccine market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Tumour Vaccine.
Chapter 13, to describe Tumour Vaccine research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Tumour Vaccine
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Tumour Vaccine by Type
        1.3.1 Overview: Global Tumour Vaccine Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Tumour Vaccine Consumption Value Market Share by Type in 2023
        1.3.3 Personalized Vaccine
        1.3.4 Off-the shelf Vaccine
    1.4 Global Tumour Vaccine Market by Application
        1.4.1 Overview: Global Tumour Vaccine Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Lung Cancer
        1.4.3 Melanoma Cancer
        1.4.4 Gastrointestinal Cancer
        1.4.5 Brain Cancer
        1.4.6 Others
    1.5 Global Tumour Vaccine Market Size & Forecast
    1.6 Global Tumour Vaccine Market Size and Forecast by Region
        1.6.1 Global Tumour Vaccine Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Tumour Vaccine Market Size by Region, (2019-2030)
        1.6.3 North America Tumour Vaccine Market Size and Prospect (2019-2030)
        1.6.4 Europe Tumour Vaccine Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Tumour Vaccine Market Size and Prospect (2019-2030)
        1.6.6 South America Tumour Vaccine Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Tumour Vaccine Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer Tumour Vaccine Product and Solutions
        2.1.4 Pfizer Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Pfizer Recent Developments and Future Plans
    2.2 Merck & Co Inc
        2.2.1 Merck & Co Inc Details
        2.2.2 Merck & Co Inc Major Business
        2.2.3 Merck & Co Inc Tumour Vaccine Product and Solutions
        2.2.4 Merck & Co Inc Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Merck & Co Inc Recent Developments and Future Plans
    2.3 Eli Lilly and Company
        2.3.1 Eli Lilly and Company Details
        2.3.2 Eli Lilly and Company Major Business
        2.3.3 Eli Lilly and Company Tumour Vaccine Product and Solutions
        2.3.4 Eli Lilly and Company Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Eli Lilly and Company Recent Developments and Future Plans
    2.4 BioNTech
        2.4.1 BioNTech Details
        2.4.2 BioNTech Major Business
        2.4.3 BioNTech Tumour Vaccine Product and Solutions
        2.4.4 BioNTech Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 BioNTech Recent Developments and Future Plans
    2.5 Roche Holding AG
        2.5.1 Roche Holding AG Details
        2.5.2 Roche Holding AG Major Business
        2.5.3 Roche Holding AG Tumour Vaccine Product and Solutions
        2.5.4 Roche Holding AG Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Roche Holding AG Recent Developments and Future Plans
    2.6 OSE Immunotherapeutics
        2.6.1 OSE Immunotherapeutics Details
        2.6.2 OSE Immunotherapeutics Major Business
        2.6.3 OSE Immunotherapeutics Tumour Vaccine Product and Solutions
        2.6.4 OSE Immunotherapeutics Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 OSE Immunotherapeutics Recent Developments and Future Plans
    2.7 Gritstone Bio
        2.7.1 Gritstone Bio Details
        2.7.2 Gritstone Bio Major Business
        2.7.3 Gritstone Bio Tumour Vaccine Product and Solutions
        2.7.4 Gritstone Bio Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Gritstone Bio Recent Developments and Future Plans
    2.8 Moderna
        2.8.1 Moderna Details
        2.8.2 Moderna Major Business
        2.8.3 Moderna Tumour Vaccine Product and Solutions
        2.8.4 Moderna Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Moderna Recent Developments and Future Plans
    2.9 Avidea Technologies
        2.9.1 Avidea Technologies Details
        2.9.2 Avidea Technologies Major Business
        2.9.3 Avidea Technologies Tumour Vaccine Product and Solutions
        2.9.4 Avidea Technologies Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Avidea Technologies Recent Developments and Future Plans
    2.10 Vaccibody AS
        2.10.1 Vaccibody AS Details
        2.10.2 Vaccibody AS Major Business
        2.10.3 Vaccibody AS Tumour Vaccine Product and Solutions
        2.10.4 Vaccibody AS Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Vaccibody AS Recent Developments and Future Plans
    2.11 Agenus Inc
        2.11.1 Agenus Inc Details
        2.11.2 Agenus Inc Major Business
        2.11.3 Agenus Inc Tumour Vaccine Product and Solutions
        2.11.4 Agenus Inc Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 Agenus Inc Recent Developments and Future Plans
    2.12 Novogene
        2.12.1 Novogene Details
        2.12.2 Novogene Major Business
        2.12.3 Novogene Tumour Vaccine Product and Solutions
        2.12.4 Novogene Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 Novogene Recent Developments and Future Plans
    2.13 ZIOPHARM Oncology
        2.13.1 ZIOPHARM Oncology Details
        2.13.2 ZIOPHARM Oncology Major Business
        2.13.3 ZIOPHARM Oncology Tumour Vaccine Product and Solutions
        2.13.4 ZIOPHARM Oncology Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.13.5 ZIOPHARM Oncology Recent Developments and Future Plans
    2.14 ISA Pharmaceuticals
        2.14.1 ISA Pharmaceuticals Details
        2.14.2 ISA Pharmaceuticals Major Business
        2.14.3 ISA Pharmaceuticals Tumour Vaccine Product and Solutions
        2.14.4 ISA Pharmaceuticals Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.14.5 ISA Pharmaceuticals Recent Developments and Future Plans
    2.15 BrightPath Biotherapeutics
        2.15.1 BrightPath Biotherapeutics Details
        2.15.2 BrightPath Biotherapeutics Major Business
        2.15.3 BrightPath Biotherapeutics Tumour Vaccine Product and Solutions
        2.15.4 BrightPath Biotherapeutics Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.15.5 BrightPath Biotherapeutics Recent Developments and Future Plans
    2.16 Vaximm AG
        2.16.1 Vaximm AG Details
        2.16.2 Vaximm AG Major Business
        2.16.3 Vaximm AG Tumour Vaccine Product and Solutions
        2.16.4 Vaximm AG Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.16.5 Vaximm AG Recent Developments and Future Plans
    2.17 Medigene AG
        2.17.1 Medigene AG Details
        2.17.2 Medigene AG Major Business
        2.17.3 Medigene AG Tumour Vaccine Product and Solutions
        2.17.4 Medigene AG Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.17.5 Medigene AG Recent Developments and Future Plans
    2.18 Genocea Biosciences Inc
        2.18.1 Genocea Biosciences Inc Details
        2.18.2 Genocea Biosciences Inc Major Business
        2.18.3 Genocea Biosciences Inc Tumour Vaccine Product and Solutions
        2.18.4 Genocea Biosciences Inc Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.18.5 Genocea Biosciences Inc Recent Developments and Future Plans
    2.19 Advaxis
        2.19.1 Advaxis Details
        2.19.2 Advaxis Major Business
        2.19.3 Advaxis Tumour Vaccine Product and Solutions
        2.19.4 Advaxis Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.19.5 Advaxis Recent Developments and Future Plans
    2.20 Nouscom
        2.20.1 Nouscom Details
        2.20.2 Nouscom Major Business
        2.20.3 Nouscom Tumour Vaccine Product and Solutions
        2.20.4 Nouscom Tumour Vaccine Revenue, Gross Margin and Market Share (2019-2024)
        2.20.5 Nouscom Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Tumour Vaccine Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Tumour Vaccine by Company Revenue
        3.2.2 Top 3 Tumour Vaccine Players Market Share in 2023
        3.2.3 Top 6 Tumour Vaccine Players Market Share in 2023
    3.3 Tumour Vaccine Market: Overall Company Footprint Analysis
        3.3.1 Tumour Vaccine Market: Region Footprint
        3.3.2 Tumour Vaccine Market: Company Product Type Footprint
        3.3.3 Tumour Vaccine Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Tumour Vaccine Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Tumour Vaccine Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Tumour Vaccine Consumption Value Market Share by Application (2019-2024)
    5.2 Global Tumour Vaccine Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Tumour Vaccine Consumption Value by Type (2019-2030)
    6.2 North America Tumour Vaccine Consumption Value by Application (2019-2030)
    6.3 North America Tumour Vaccine Market Size by Country
        6.3.1 North America Tumour Vaccine Consumption Value by Country (2019-2030)
        6.3.2 United States Tumour Vaccine Market Size and Forecast (2019-2030)
        6.3.3 Canada Tumour Vaccine Market Size and Forecast (2019-2030)
        6.3.4 Mexico Tumour Vaccine Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Tumour Vaccine Consumption Value by Type (2019-2030)
    7.2 Europe Tumour Vaccine Consumption Value by Application (2019-2030)
    7.3 Europe Tumour Vaccine Market Size by Country
        7.3.1 Europe Tumour Vaccine Consumption Value by Country (2019-2030)
        7.3.2 Germany Tumour Vaccine Market Size and Forecast (2019-2030)
        7.3.3 France Tumour Vaccine Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Tumour Vaccine Market Size and Forecast (2019-2030)
        7.3.5 Russia Tumour Vaccine Market Size and Forecast (2019-2030)
        7.3.6 Italy Tumour Vaccine Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Tumour Vaccine Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Tumour Vaccine Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Tumour Vaccine Market Size by Region
        8.3.1 Asia-Pacific Tumour Vaccine Consumption Value by Region (2019-2030)
        8.3.2 China Tumour Vaccine Market Size and Forecast (2019-2030)
        8.3.3 Japan Tumour Vaccine Market Size and Forecast (2019-2030)
        8.3.4 South Korea Tumour Vaccine Market Size and Forecast (2019-2030)
        8.3.5 India Tumour Vaccine Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Tumour Vaccine Market Size and Forecast (2019-2030)
        8.3.7 Australia Tumour Vaccine Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Tumour Vaccine Consumption Value by Type (2019-2030)
    9.2 South America Tumour Vaccine Consumption Value by Application (2019-2030)
    9.3 South America Tumour Vaccine Market Size by Country
        9.3.1 South America Tumour Vaccine Consumption Value by Country (2019-2030)
        9.3.2 Brazil Tumour Vaccine Market Size and Forecast (2019-2030)
        9.3.3 Argentina Tumour Vaccine Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Tumour Vaccine Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Tumour Vaccine Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Tumour Vaccine Market Size by Country
        10.3.1 Middle East & Africa Tumour Vaccine Consumption Value by Country (2019-2030)
        10.3.2 Turkey Tumour Vaccine Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Tumour Vaccine Market Size and Forecast (2019-2030)
        10.3.4 UAE Tumour Vaccine Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Tumour Vaccine Market Drivers
    11.2 Tumour Vaccine Market Restraints
    11.3 Tumour Vaccine Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Tumour Vaccine Industry Chain
    12.2 Tumour Vaccine Upstream Analysis
    12.3 Tumour Vaccine Midstream Analysis
    12.4 Tumour Vaccine Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Tumour Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Tumour Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Tumour Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Tumour Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Pfizer Company Information, Head Office, and Major Competitors
    Table 6. Pfizer Major Business
    Table 7. Pfizer Tumour Vaccine Product and Solutions
    Table 8. Pfizer Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Pfizer Recent Developments and Future Plans
    Table 10. Merck & Co Inc Company Information, Head Office, and Major Competitors
    Table 11. Merck & Co Inc Major Business
    Table 12. Merck & Co Inc Tumour Vaccine Product and Solutions
    Table 13. Merck & Co Inc Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Merck & Co Inc Recent Developments and Future Plans
    Table 15. Eli Lilly and Company Company Information, Head Office, and Major Competitors
    Table 16. Eli Lilly and Company Major Business
    Table 17. Eli Lilly and Company Tumour Vaccine Product and Solutions
    Table 18. Eli Lilly and Company Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Eli Lilly and Company Recent Developments and Future Plans
    Table 20. BioNTech Company Information, Head Office, and Major Competitors
    Table 21. BioNTech Major Business
    Table 22. BioNTech Tumour Vaccine Product and Solutions
    Table 23. BioNTech Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. BioNTech Recent Developments and Future Plans
    Table 25. Roche Holding AG Company Information, Head Office, and Major Competitors
    Table 26. Roche Holding AG Major Business
    Table 27. Roche Holding AG Tumour Vaccine Product and Solutions
    Table 28. Roche Holding AG Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Roche Holding AG Recent Developments and Future Plans
    Table 30. OSE Immunotherapeutics Company Information, Head Office, and Major Competitors
    Table 31. OSE Immunotherapeutics Major Business
    Table 32. OSE Immunotherapeutics Tumour Vaccine Product and Solutions
    Table 33. OSE Immunotherapeutics Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. OSE Immunotherapeutics Recent Developments and Future Plans
    Table 35. Gritstone Bio Company Information, Head Office, and Major Competitors
    Table 36. Gritstone Bio Major Business
    Table 37. Gritstone Bio Tumour Vaccine Product and Solutions
    Table 38. Gritstone Bio Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. Gritstone Bio Recent Developments and Future Plans
    Table 40. Moderna Company Information, Head Office, and Major Competitors
    Table 41. Moderna Major Business
    Table 42. Moderna Tumour Vaccine Product and Solutions
    Table 43. Moderna Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Moderna Recent Developments and Future Plans
    Table 45. Avidea Technologies Company Information, Head Office, and Major Competitors
    Table 46. Avidea Technologies Major Business
    Table 47. Avidea Technologies Tumour Vaccine Product and Solutions
    Table 48. Avidea Technologies Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. Avidea Technologies Recent Developments and Future Plans
    Table 50. Vaccibody AS Company Information, Head Office, and Major Competitors
    Table 51. Vaccibody AS Major Business
    Table 52. Vaccibody AS Tumour Vaccine Product and Solutions
    Table 53. Vaccibody AS Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 54. Vaccibody AS Recent Developments and Future Plans
    Table 55. Agenus Inc Company Information, Head Office, and Major Competitors
    Table 56. Agenus Inc Major Business
    Table 57. Agenus Inc Tumour Vaccine Product and Solutions
    Table 58. Agenus Inc Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 59. Agenus Inc Recent Developments and Future Plans
    Table 60. Novogene Company Information, Head Office, and Major Competitors
    Table 61. Novogene Major Business
    Table 62. Novogene Tumour Vaccine Product and Solutions
    Table 63. Novogene Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 64. Novogene Recent Developments and Future Plans
    Table 65. ZIOPHARM Oncology Company Information, Head Office, and Major Competitors
    Table 66. ZIOPHARM Oncology Major Business
    Table 67. ZIOPHARM Oncology Tumour Vaccine Product and Solutions
    Table 68. ZIOPHARM Oncology Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 69. ZIOPHARM Oncology Recent Developments and Future Plans
    Table 70. ISA Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 71. ISA Pharmaceuticals Major Business
    Table 72. ISA Pharmaceuticals Tumour Vaccine Product and Solutions
    Table 73. ISA Pharmaceuticals Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 74. ISA Pharmaceuticals Recent Developments and Future Plans
    Table 75. BrightPath Biotherapeutics Company Information, Head Office, and Major Competitors
    Table 76. BrightPath Biotherapeutics Major Business
    Table 77. BrightPath Biotherapeutics Tumour Vaccine Product and Solutions
    Table 78. BrightPath Biotherapeutics Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 79. BrightPath Biotherapeutics Recent Developments and Future Plans
    Table 80. Vaximm AG Company Information, Head Office, and Major Competitors
    Table 81. Vaximm AG Major Business
    Table 82. Vaximm AG Tumour Vaccine Product and Solutions
    Table 83. Vaximm AG Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 84. Vaximm AG Recent Developments and Future Plans
    Table 85. Medigene AG Company Information, Head Office, and Major Competitors
    Table 86. Medigene AG Major Business
    Table 87. Medigene AG Tumour Vaccine Product and Solutions
    Table 88. Medigene AG Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 89. Medigene AG Recent Developments and Future Plans
    Table 90. Genocea Biosciences Inc Company Information, Head Office, and Major Competitors
    Table 91. Genocea Biosciences Inc Major Business
    Table 92. Genocea Biosciences Inc Tumour Vaccine Product and Solutions
    Table 93. Genocea Biosciences Inc Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 94. Genocea Biosciences Inc Recent Developments and Future Plans
    Table 95. Advaxis Company Information, Head Office, and Major Competitors
    Table 96. Advaxis Major Business
    Table 97. Advaxis Tumour Vaccine Product and Solutions
    Table 98. Advaxis Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 99. Advaxis Recent Developments and Future Plans
    Table 100. Nouscom Company Information, Head Office, and Major Competitors
    Table 101. Nouscom Major Business
    Table 102. Nouscom Tumour Vaccine Product and Solutions
    Table 103. Nouscom Tumour Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 104. Nouscom Recent Developments and Future Plans
    Table 105. Global Tumour Vaccine Revenue (USD Million) by Players (2019-2024)
    Table 106. Global Tumour Vaccine Revenue Share by Players (2019-2024)
    Table 107. Breakdown of Tumour Vaccine by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 108. Market Position of Players in Tumour Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 109. Head Office of Key Tumour Vaccine Players
    Table 110. Tumour Vaccine Market: Company Product Type Footprint
    Table 111. Tumour Vaccine Market: Company Product Application Footprint
    Table 112. Tumour Vaccine New Market Entrants and Barriers to Market Entry
    Table 113. Tumour Vaccine Mergers, Acquisition, Agreements, and Collaborations
    Table 114. Global Tumour Vaccine Consumption Value (USD Million) by Type (2019-2024)
    Table 115. Global Tumour Vaccine Consumption Value Share by Type (2019-2024)
    Table 116. Global Tumour Vaccine Consumption Value Forecast by Type (2025-2030)
    Table 117. Global Tumour Vaccine Consumption Value by Application (2019-2024)
    Table 118. Global Tumour Vaccine Consumption Value Forecast by Application (2025-2030)
    Table 119. North America Tumour Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 120. North America Tumour Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 121. North America Tumour Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 122. North America Tumour Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 123. North America Tumour Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 124. North America Tumour Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 125. Europe Tumour Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 126. Europe Tumour Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 127. Europe Tumour Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 128. Europe Tumour Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 129. Europe Tumour Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 130. Europe Tumour Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 131. Asia-Pacific Tumour Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 132. Asia-Pacific Tumour Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 133. Asia-Pacific Tumour Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 134. Asia-Pacific Tumour Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 135. Asia-Pacific Tumour Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 136. Asia-Pacific Tumour Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 137. South America Tumour Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 138. South America Tumour Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 139. South America Tumour Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 140. South America Tumour Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 141. South America Tumour Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 142. South America Tumour Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 143. Middle East & Africa Tumour Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 144. Middle East & Africa Tumour Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 145. Middle East & Africa Tumour Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 146. Middle East & Africa Tumour Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 147. Middle East & Africa Tumour Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 148. Middle East & Africa Tumour Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 149. Tumour Vaccine Raw Material
    Table 150. Key Suppliers of Tumour Vaccine Raw Materials
List of Figures
    Figure 1. Tumour Vaccine Picture
    Figure 2. Global Tumour Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Tumour Vaccine Consumption Value Market Share by Type in 2023
    Figure 4. Personalized Vaccine
    Figure 5. Off-the shelf Vaccine
    Figure 6. Global Tumour Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 7. Tumour Vaccine Consumption Value Market Share by Application in 2023
    Figure 8. Lung Cancer Picture
    Figure 9. Melanoma Cancer Picture
    Figure 10. Gastrointestinal Cancer Picture
    Figure 11. Brain Cancer Picture
    Figure 12. Others Picture
    Figure 13. Global Tumour Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 14. Global Tumour Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 15. Global Market Tumour Vaccine Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 16. Global Tumour Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 17. Global Tumour Vaccine Consumption Value Market Share by Region in 2023
    Figure 18. North America Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 20. Asia-Pacific Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 21. South America Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 22. Middle East and Africa Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 23. Global Tumour Vaccine Revenue Share by Players in 2023
    Figure 24. Tumour Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 25. Global Top 3 Players Tumour Vaccine Market Share in 2023
    Figure 26. Global Top 6 Players Tumour Vaccine Market Share in 2023
    Figure 27. Global Tumour Vaccine Consumption Value Share by Type (2019-2024)
    Figure 28. Global Tumour Vaccine Market Share Forecast by Type (2025-2030)
    Figure 29. Global Tumour Vaccine Consumption Value Share by Application (2019-2024)
    Figure 30. Global Tumour Vaccine Market Share Forecast by Application (2025-2030)
    Figure 31. North America Tumour Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 32. North America Tumour Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 33. North America Tumour Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 34. United States Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 35. Canada Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 36. Mexico Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 37. Europe Tumour Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 38. Europe Tumour Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 39. Europe Tumour Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 40. Germany Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 41. France Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 42. United Kingdom Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 43. Russia Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 44. Italy Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 45. Asia-Pacific Tumour Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 46. Asia-Pacific Tumour Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 47. Asia-Pacific Tumour Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 48. China Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 49. Japan Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 50. South Korea Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 51. India Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 52. Southeast Asia Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 53. Australia Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 54. South America Tumour Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 55. South America Tumour Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 56. South America Tumour Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 57. Brazil Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 58. Argentina Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 59. Middle East and Africa Tumour Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 60. Middle East and Africa Tumour Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 61. Middle East and Africa Tumour Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 62. Turkey Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 63. Saudi Arabia Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 64. UAE Tumour Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 65. Tumour Vaccine Market Drivers
    Figure 66. Tumour Vaccine Market Restraints
    Figure 67. Tumour Vaccine Market Trends
    Figure 68. Porters Five Forces Analysis
    Figure 69. Manufacturing Cost Structure Analysis of Tumour Vaccine in 2023
    Figure 70. Manufacturing Process Analysis of Tumour Vaccine
    Figure 71. Tumour Vaccine Industrial Chain
    Figure 72. Methodology
    Figure 73. Research Process and Data Source

Companies Mentioned

Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom